Stealth BioTherapeutics Announces Positive End-of-Phase 2 Meeting with FDA on the Development of Elamipretide in Patients with Dry Age-related Macular Degeneration
Elamipretide showed favorable effect on photoreceptor integrity (ellipsoid zone attenuation) and visual function (low light – best corrected visual acuity) Positive end-of-phase 2 FDA meeting confirmed ellipsoid zone attenuation as an approvable clinical trial endpoint in dry AMD NEEDHAM, Mass., June 12, 2023 /PRNewswire/ — Stealth BioTherapeutics Inc. (the “Company” or “Stealth BioTherapeutics”), a clinical-stage … Read more